Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cytosorbents Cor (CTSO)

Cytosorbents Cor (CTSO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,021
  • Shares Outstanding, K 54,306
  • Annual Sales, $ 36,350 K
  • Annual Income, $ -28,510 K
  • 60-Month Beta 0.57
  • Price/Sales 1.55
  • Price/Cash Flow N/A
  • Price/Book 2.98
Trade CTSO with:

Options Overview Details

View History
  • Implied Volatility 223.27% ( +11.58%)
  • Historical Volatility 84.17%
  • IV Percentile 47%
  • IV Rank 16.65%
  • IV High 1,159.71% on 01/19/24
  • IV Low 36.15% on 09/21/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 5
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 472
  • Open Int (30-Day) 472

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.09
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.10
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +35.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7000 +48.57%
on 07/01/24
1.1700 -11.11%
on 07/09/24
+0.2400 (+30.00%)
since 06/21/24
3-Month
0.7000 +48.57%
on 07/01/24
1.1700 -11.11%
on 07/09/24
+0.2300 (+28.40%)
since 04/22/24
52-Week
0.7000 +48.57%
on 07/01/24
3.8500 -72.99%
on 07/25/23
-2.7050 (-72.23%)
since 07/21/23

Most Recent Stories

More News
CytoSorbents: Q1 Earnings Snapshot

CytoSorbents: Q1 Earnings Snapshot

CTSO : 1.0402 (-0.93%)
CytoSorbents: Q3 Earnings Snapshot

CytoSorbents: Q3 Earnings Snapshot

CTSO : 1.0402 (-0.93%)
CytoSorbents Completes U.S. and Canadian STAR-T Pivotal Trial

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using...

CTSO : 1.0402 (-0.93%)
CytoSorbents: Q2 Earnings Snapshot

CytoSorbents: Q2 Earnings Snapshot

CTSO : 1.0402 (-0.93%)
CytoSorbents: Q1 Earnings Snapshot

CytoSorbents: Q1 Earnings Snapshot

CTSO : 1.0402 (-0.93%)
CytoSorbents to Present at the Cowen 43rd Annual Health Care Conference

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 1.0402 (-0.93%)
CytoSorbents to Report Fiscal 2022 Operating and Financial Results

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 1.0402 (-0.93%)
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 1.0402 (-0.93%)
CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 1.0402 (-0.93%)
CytoSorbents Receives $5M in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement

/PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac...

CTSO : 1.0402 (-0.93%)

Business Summary

CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product...

See More

Key Turning Points

3rd Resistance Point 1.1632
2nd Resistance Point 1.1166
1st Resistance Point 1.0833
Last Price 1.0402
1st Support Level 1.0034
2nd Support Level 0.9568
3rd Support Level 0.9235

See More

52-Week High 3.8500
Fibonacci 61.8% 2.6467
Fibonacci 50% 2.2750
Fibonacci 38.2% 1.9033
Last Price 1.0402
52-Week Low 0.7000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar